U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-QSB

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934 For the Quarterly Period Ended March 31, 2002
                                                         ----------------

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
      For the Transition Period from              to
                                     ------------    -------------

                           Commission File No. 0-20598

                             VITALLABS, INC.
             (exact name of registrant as specified in its charter)

         NEVADA                                                 75-2293489
 (State or other jurisdiction of                            (IRS Employer
 incorporation organization)                                Identification
No.)

         1375 South Fort Harrison Avenue, Clearwater, Florida 33756
         -------------------------------------------------------------
          (Address of principle executive offices, including zip code)

                                  727-461-3200
                                -----------------
              (Registrant's telephone number, including area code)

                             Monogram Pictures, Inc.
                    -----------------------------------------
                                 (Former name)

Indicate by check mark whether the registrant (1) has filed all reports
required by Section 13 or 15(d) of the Securities and Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes [x] No [ ]

The number of shares of the registrant's common stock, $0.001 par value, as
of May 18, 2002 80,056,360

                             VITALLABS, INC.
                    FORM 10-QSB, QUARTER ENDED MARCH 31, 2002

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1 - Financial Statements
Consolidated Balance Sheets as of March 31, 2002                            1
Consolidated Statements of Operations for the
 Three Months Ended March 31, 2002.and 2001                                 2
Consolidated Statements of Cash Flows
 for the Three Months Ended March 31, 2002.and 2001                         3
Notes to Interim Consolidated Financial Statements                          4

All schedules are omitted because they are not applicable or the required
information is shown in the financial statements or notes thereto.

Item 2 - Management's Discussion and Analysis                               5

PART II - OTHER INFORMATION

Item 1 - Legal Proceedings..........................................  ..... 6
Item 2 - Changes in Securities............................................. 6
Item 3 - Defaults Upon Senior Securities................................... 6
Item 4 - Submission of Matters to a Vote of Security Holders............... 6
Item 5 - Other Information................................................. 6
Item 6 - Exhibits and Reports on Form 8-K.................................. 6
 Signatures................................................................ 6





PART I

Item 1.  Financial Statements.

                             VITALLABS, INC.
<TABLE>
                           CONSOLIDATED BALANCE SHEETS
                           MARCH 31, 2002 (Unaudited)
<S>                                                       <C>
Assets
Current assets:
  Cash                                                    $          0

Property and equipment, net of accumulated depreciation           2,790

Other assets                                                        163
                                                          -------------

                                                          $       2,953
                                                          =============


Liabilities and Stockholders' Deficit
Current liabilities:
  Cash Over Draft                                         $         527
  Note payable                                                   34,061
  Accounts payable and accrued expenses                         139,136
  Due to related parties                                         38,508
  Net liabilities of discontinued operations,
    Including related party payable of $39,131                   60,667
                                                          -------------
Total current liabilities                                       272,899
                                                          -------------

Common stock payable                                             58,700
                                                          -------------

Stockholders' deficit:
  Preferred stock; $.01 par value; 5,000,000 shares
     authorized; 17,500 shares issued and outstanding               175
  Common stock; $.001 par value; 100,000,000 shares
     authorized; 17,145,286 shares issued and
     outstanding                                                 17,145
  Additional Paid In Capital                                 22,689,467
  Accumulated deficit                                       (23,035,433)
                                                          -------------
Total stockholders' deficit                                    (328,646)
                                                          -------------

                                                          $       2,953
                                                          =============

<FN>
See notes to condensed financial statements.
</TABLE>
-------------------------------------------------------------------------------
<PAGE>



                                Vitallabs, Inc.
<TABLE>
                     CONSOLIDATED STATEMENTS OF OPERATIONS
         FOR THE THREE MONTHS ENDED MARCH 31, 2002 AND 2001 (Unaudited)


<CAPTION>
                                               Three Months      Three Months
                                                  Ended             Ended
                                             March 31, 2002    March 31, 2001
                                              --------------    -------------
-
<S>                                         <C>               <C>
Revenues                                     $           0     $           0

General and administrative expenses                89,735            185,483
                                            ---------------   ---------------
Net loss from continuing operations               (89,735)          (185,483)
                                            ---------------   ---------------

Discontinued operations:
  Loss from operations of Medical
    Discount Limited, Inc. discontinued
    segment                                       (32,335)            -
  Loss from operations of General
    Personnel Management, Inc.
    discontinued segment                                           (20,302)
                                            ---------------   ---------------
Total discontinued operations                     (32,335)         (20,302)
                                            ---------------   ---------------

Net loss                                    $    (122,070)   $    (205,785 )
                                            ===============   ===============

Basic loss per share:
  Loss from continuing operations           $       (.01)    $       (.08)
  Loss from operations of Medical
    Discount Limited, Inc. discontinued
    segment                                         (.00)
  Loss from operations of General
    Personnel Management, Inc.
    discontinued segment                                             (.01)
                                            ---------------   ---------------
  Basic Net Loss Per Share                  $       (.01)    $       (.09)
                                            ===============   ===============

Weighted average number of common shares
  used in basic loss per share calculations    17,100,842        2,355,089
                                            ===============   ===============

<FN>
See notes to condensed financial statements.
</TABLE>



                                Vitallabs, Inc.
<TABLE>
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
         FOR THE THREE MONTHS ENDED MARCH 31, 2002 AND 2001 (Unaudited)
<CAPTION>
                                               Three Months      Three Months
                                                   Ended             Ended
                                             March 31, 2002    March 31, 2001
                                              --------------    -------------
-
<S>                                           <C>               <C>
Cash Flows From Operating Activities
   Net Loss                                    $ (122,070)       $  (205,785)
   Adjustments to Reconcile Net
    Loss to Net Cash Flows Used in
    Operating Activities
      Common Stock Issued for Services             80,000            110,000
      Depreciation                                    219             14,164
   Changes in Assets and Liabilities
     Decrease in Prepaid Expenses                      0               4,764
     Increase in Accounts
       Payable and Accrued Liabilities              7,881             11,362
     Increase in Net Liabilities of
       Discontinued Operations                     30,885                0
                                                -----------       -----------
   Total Adjustments                              118,985            140,290
                                                -----------       -----------
Net Cash Flows Used In Operating Activities        (3,085)           (65,495)

Cash Flows From Financing Activities
   Advances From Related Party                      1,500                0
   Proceeds from sale of securities                 1,000                0
                                                 -----------       ----------
-

Net Cash Flows Provided By Financing
Activities                                          2,500                0
                                                -----------       -----------

Decrease in Cash                                     (585)           (65,495)
Cash Beginning of Period                               58             65,588
                                                -----------       -----------
Cash End of Period                              $     (527)        $       93
                                                ===========       ===========

Supplemental Disclosure of Cash Flow Information:
Cash paid for:
   Interest                                     $         0       $         0
                                                ===========       ===========
   Income taxes                                 $         0       $         0
                                                ===========       ===========

Supplemental Schedule of Noncash
  Investing and Financing Activities:
      Issuance of Common Stock for
       Services Rendered                            80,000        $   110,000
                                                ===========       ===========
<FN>
See notes to condensed financial statements.
</TABLE>


                                VITALLABS, INC.
               NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
                          MARCH 31, 2002 (unaudited)

NOTE 1.  Statement of Information Furnished

The accompanying unaudited interim consolidated financial statements have
been prepared in accordance with Form 10-QSB instructions and in the opinion
of management contains all adjustments (consisting of only normal recurring
adjustments) necessary to present fairly the financial position as of March
31, 2002, and the consolidated results of operations and cash flows for the
three months ended March 31, 2002 and 2001. These results have been
determined on the basis of generally accepted accounting principles and
practices and applied consistently with those used in the preparation of the
Company's 2001 Annual Report on Form 10-KSB.  Results for the three months
ended March 31, 2002 are not indicative of the results expected for the year
ended December 31, 2002.

Certain information and footnote disclosure normally included in the
financial statements presented in accordance with generally accepted
accounting principles have been condensed or omitted. It is suggested that
the accompanying consolidated financial statements be read in conjunction
with the accompanying consolidated financial statements and notes thereto
incorporated by reference in the Company's 2001 Annual Report on Form 10-KSB.

NOTE 2.  Going Concern

The accompanying consolidated financial statements have been prepared
assuming the Company will continue as a going concern.  The Company has
incurred significant loses from operations for the last 2 years, had negative
working capital of approximately $273,000 at March 31, 2002 and its
liabilities exceed its assets by approximately $329,000 at March 31, 2002.
In addition, as more fully described in the Form 10KSB dated December 31,
2001, the company subsequent to year end had acquired another company which
is experiencing financial difficulties.  These factors and others raise
substantial doubt about its ability to continue as a going concern.  New
management is currently looking in to raising additional funds for the
Company by means of a private placement of some of the Company's equity
securities although no assurance can be given regarding how successful that
private placement may be.  The consolidated financial statements do not
include any adjustments that might result from the outcome of these
uncertainties.

NOTE 3.  Recent Events

On November 19, 2001, the Company entered into a Letter of Intent with A.S.K.
Consulting, Inc. ("ASK"), a related party.  ASK is a consulting firm whose
president is also a director and officer of the Company.  ASK is seeking to
locate another entity ("target") to form a business combination with the
Company.

The Letter of Intent contains certain anti-dilutive provisions indicating, in
summary, that the then present holders of the outstanding common stock of the
Company at the conclusion of the anticipated business combination transaction
will own not less than four percent of the shares of the Company's common
stock outstanding immediately subsequent to the consummation of the business
combination transaction.  Such anti-dilutive provisions shall be effective
for a period of 12 months from the date of any definitive agreement that
governs the business combination transaction between the Company and Target.

In accordance with the Letter of Intent, the Company is required to take all
appropriate and necessary steps to permit the distribution of substantially
all of the common stock of Medical Discounts Limited, Inc. (MDL), the

Company's wholly owned subsidiary to the present holders of the outstanding
common stock of the Company.  Such distribution is required to be
accomplished in accordance with a registration statement to be filed under
the Securities Act of 1933, as amended, which will contain a form of
prospectus.  Prior and subsequent to such anticipated distribution, MDL will
continue to conduct its present business under its present management.  In
connection with the intended distribution of MDL common stock, ASK is
required to facilitate the purchase by the Company for $135,000 the number of
shares of MDL common stock that will equal five percent of the common stock
to be outstanding at the conclusion of the distribution which is anticipated
to be 50,000 shares.  ASK is required, per the Letter of Intent, to loan the
Company $135,000 to fund this transaction.

The Company has shown MDL as a discontinued operation in the accompanying
consolidated financial statements.

In addition, ASK is required to engage legal counsel for $20,000 to provide
for and defray the legal fees to be incurred by MDL in connection with the
preparation, filing, and processing to effectiveness of the registration
statement relating to the distribution of MDL's common stock.

The Letter of Intent further provides that the presently outstanding 17,500
shares of preferred stock will be redeemed or cancelled prior to the time
that a definitive agreement is entered into between the Company and Target.

On January 25, 2002, the Company entered into an Agreement to acquire all of
the outstanding voting common stock of Med-Tech Labs, Inc.("MSA")  Such voting
common stock is comprised of 7,500 shares of $1.00 par value stock.  MSA
conducts its business under the name of MedServices of America.

Pursuant to the terms of the Agreement, all of the outstanding voting common
stock of MSA will be exchanged for that number of shares of the Company's
common stock which, when issued, will constitute 95 percent of the Company's
common stock then outstanding. This transaction will be accounted for as a
reverse merger, with MSA accounted for as the acquiror for financial statement
purposes.  This transaction closed effective April 05, 2002

Generally accepted accounting principals in the United States of America
require that if a business combination is closed subsequent to the balance
sheet date but prior to the time that the financial statements are issued then
a condensed balance sheet disclosing the amount assigned to each major asset
and liability caption of the acquired entity at the acquisition date and
certain other items be disclosed unless it is not practicable to do so  That
condensed balance sheet and certain other information are not currently
available and have not been presented.

Although their financial Statements are not available, MSA has experienced
several problems primarily with payments both from Medicare and from individual
clients.  The results of operations were severely impacted by these events
which has resulted in large losses for the year ended December 31, 2001.  In
addition, liabilities exceed total assets as of December 31, 2001.

Management has estimated it will need approximate $3,000,000 in debt/equity
financial to complete its short term business plan which include the
acquisition of other existing labs.  There can be no assurance that Vitallabs
will be able to obtain additional financing, or if successful, that it will be
able to do so on terms that are reasonable in light of current market
conditions.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.

When used in this discussion, the words "believes", "anticipates", "expects",
and similar expressions are intended to identify forward-looking statements.
Such statements are subject to certain risks and uncertainties, which could
cause actual results to differ materially from those projected. Readers are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. The Company undertakes no obligation
to republish revised forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. Readers are also urged to carefully review and consider
the various disclosures made by the Company which attempt to advise
interested parties of the factors which affect the Company's business, in
this report, as well as the Company's periodic reports on Forms 10-KSB, 10-
QSB and 8-K filed with the Securities and Exchange Commission.

RESULTS OF OPERATIONS

REVENUES.
Vitallabs did not generate any revenue for the periods ended March 31, 2002
and 2001.  The Company's subsidiaries, have been reported in its financial
statements as discontinued segments.

Vitallabs has disclosed on its annually report on form 10KSB its
contractually obligated to distribute 95% of the common stock of MDL to its
stockholder.  Therefore, Vitallabs has shown MDL's operations as a
discontinued segment.  Net sales of MDL for the period March 31, 2002 was
$6,296.  Net sales for GPM for the period March 31, 2001 was $453,259, there
was no revenue for the period ended March 31, 2002.  These amounts are
included in loss on operations of discontinued segments in the accompanying
consolidated statements of operations.  As a result of this contractual
obligation goodwill previously recorded was written off and the operations
have been treated as discontinued segment for all periods presented in the
accompanying consolidated financial statements.  The loss for the period is
$32,335.


GENERAL AND ADMINISTRATIVE EXPENSES.
General and Administrative costs decreased from $185,483 in 2001 to $89,735
or a 52% decrease. The decrease was due to a reduction in stock issued for
services and the market value for the company's common stock.  Vitallabs
continues to issue common stock and options for services rendered, which
contributed to loss from operation during 2002 of $89,735 and 185,483 during
2001, a decrease of $95,748, or 52%. The services rendered are primarily
attributable to costs associated with business development of advertising and
marketing programs, public relations, and legal and accounting services,
resulting from Company's attempt to inquire into the possible acquisition or
merger with other similar lines of business.


LIQUIDITY AND CAPITAL RESOURCES
The Financial Statements of Med Tech Labs, Inc. for the years ended December
31, 2000 and 2001 are currently being audited by Vitallab's outside auditor
and will be filed on form 8k once completed.  Un-audited revenue for the year
ended December 31, 2000 was $9,530,152 and net income was $200,799.  In
January of 2001, Med Tech Labs, Inc. created a division to provide service to
the Nursing Home Industry.  Med Tech Labs, Inc. experienced several problems
with this division primarily with payment both from Medicare and from the
individual homes.  Med Tech Labs, Inc. closed this division July 13, 2001 and
terminated its relationship with these homes.  The results of operation were
severely impacted by these events.  Revenues un-audited for the year ended
December 31, 2001 was $10,886,931.  The net loss for the period was
$1,631,652 due to a write off of accounts receivable and other charge offs of
$1,946,241. The accounts receivable write off primarily consisted of accounts
acquired when the lab was purchased in 2000.  Total unaudited assets were
$4,063,625 liabilities unaudited were $5,270,981 and total stockholders
equity unaudited ($1,207,355).  Management has estimated that it needs
approximately $3,000,000 in debt/equity financial to complete its short term
business plan, which includes the acquisition of other existing labs.  There
can be no assurance that if additional funds are required they will be
available, or, if available, that they can be obtained on terms satisfactory
to Management. There can be no guarantee that Vitallabs will be able to
obtain additional financing, or if successful, that it will be able to do so
on terms that are reasonable in light of current market conditions.

Net cash flows used by operating activities during 2002 was $(3,085)
consisting primarily of net loss adjusted for noncash items such as stock
issued for services. Net cash flows used by operating activities for 2001
were $(65,495).

Net cash flows provided by financing activities were $2,500 during 2002
primarily representing proceeds from the issuance of notes payable and common
stock. Vitallabs's future funding requirements will depend on numerous
factors, some of which are beyond the Company's control.

The following information is regarding Med Tech Labs, Inc.  At December 31,
2000 total assets unaudited were $3,752,109, total liabilities unaudited were
$3,360,143 and total stockholders' equity was $391,966, unaudited.  At
December 31, 2001, total assets were $4,063,625 liabilities were $5,270,981
and total stockholders equity ($1,207,355), unaudited.  Management has
estimated that it needs approximately $3,000,000 in debt/equity financial to
complete its short term business plan, which includes the acquisition of
other existing clinical laboratories.  Med Tech currently has two contracts
which once completed will expand the market of Med Tech into the southeast
coast of Florida and further into the northwest region of Florida.  There can
be no assurance that additional funds will be available, or, if available,
that they can be obtained on terms satisfactory to Management.


PART II

ITEM 1.  LEGAL PROCEEDINGS.
MSA is a defendant in actions for collection brought by four vendors seeking
recovery of an aggregate amount of less than $100,000.  Management believes
that an adverse outcome in one or more of these suits would not have a
material adverse effect on the business and prospects of MSA.  MSA may be
involved in various claims and legal actions arising in the ordinary course
of business.  These matters may include, but are not limited to, professional
liability, employee related matters, and inquiries from governmental agencies
and Medicare or Medicaid carriers requesting comment on allegations of
billing irregularities that are brought to their attention through billing
audits or third parties.

ITEM 2.  CHANGES IN SECURITIES.
For the three months ended March 31, 2002, the Company issued 2,000,000
shares of its common stock at $0.04 per share, or $80,000 for consulting
services.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.
None.

ITEM 4.  SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS.
Shareholders representing 54,000,000 shares or 67% of the Company's voting
stock approved an Amendment to the Articles of Incorporation to reflect its
corporate name change from Monogram Pictures, Inc. to Vitallabs, Inc.

ITEM 5.  OTHER INFORMATION.
None.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.

(a) Exhibits - None

(b) Reports on Form 8-K.
(1) On February 15, 2002, Vitallabs, Inc. filed on Form 8k to announce it had
entered into an "Agreement Providing for the Exchange of Capital Stock" (the
"Agreement") pursuant to which it will acquire all of the outstanding voting
common stock (the only series of equity securities outstanding) of a Florida
corporation known as Med-Tech Labs, Inc.

(2) On March 8, 2002, Vitallabs, Inc. filed on Form 8k to announce on March
7th, 2002 an Internet Live Chat occurred with the new Chairman of
the Board of Monogram Pictures, Inc.  A press statement was released March
5th, 2002 announcing the chat, which was open to the general public at no
charge on the Internet.

(3) On March 14, 2002, Vitallabs, Inc. filed on Form 8k to announce the
decision to dismiss Clancy and Co., P.L.L.C. was made by the Board of
Directors.  Clancy and Co., P.L.L.C. desired to resign.  Monogram's new
management wished to retain Pender Newkirk and Co. CPA's as its auditors both
for geographic reasons and Pender's recent accounting experience with
Monogram's pending acquisition of Med-Tech Laboratories, Inc. d/b/a/ Med
Services of America.

(4) On March 20, 2002, Vitallabs, Inc. filed an amendment to the previously
filed 8K on March 14, 2002 with both auditors' confirmation letters attached.

                                   SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                                            VITALLABS, INC.


                                       By:  /s/ Thomas W. Kearney
                                      -------------------------------
Date: May 20, 2002                              Thomas W. Kearney
                                        Chief Audit and Financial Officer
                                       (Principal financial and
                                            accounting officer)


                                       By:  /s/ Edwin B. Salmon, Jr.
                                      --------------------------------
Date: May 20, 2002                              Edwin B. Salmon, Jr.
                                        Chief Executive Officer
                                        Principal executive officer)


In accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the Registrant and in the capacities and on
the dates indicated.